Novo Nordisk
NVO
559 hedge funds and large institutions have $8.89B invested in Novo Nordisk in 2019 Q2 according to their latest regulatory filings, with 53 funds opening new positions, 190 increasing their positions, 195 reducing their positions, and 69 closing their positions.
130% more call options, than puts
Call options by funds: $56.2M | Put options by funds: $24.4M
0.38% more ownership
Funds ownership: 18.35% → 18.73% (+0.38%)
3% less repeat investments, than reductions
Existing positions increased: 190 | Existing positions reduced: 195
3% less capital invested
Capital invested by funds: $9.18B → $8.89B (-$290M)
4% less funds holding
Funds holding: 580 → 559 (-21)
20% less funds holding in top 10
Funds holding in top 10: 10 → 8 (-2)
23% less first-time investments, than exits
New positions opened: 53 | Existing positions closed: 69
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
+$94.9M |
| 2 |
Renaissance Technologies
New York
|
+$58.2M |
| 3 |
AAMU
Amundi Asset Management US
Boston,
Massachusetts
|
+$47.7M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$45M |
| 5 |
Jennison Associates
New York
|
+$28.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$97.8M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$91.1M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$43.5M |
| 4 |
BlackRock
New York
|
-$28.9M |
| 5 |
Grantham, Mayo, Van Otterloo & Co (GMO)
Boston,
Massachusetts
|
-$21.9M |
NVO Hedge Fund Activity: Q2 2019 in Review
559 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Novo Nordisk (NVO) for Q2 2019, worth a combined $8.89B — down 3.2% from $9.18B a quarter earlier.
Sellers outnumbered buyers: 69 funds closed out of NVO and 53 opened new positions — a net loss of 16 holders — while 195 trimmed existing stakes and 190 added.
The largest buyer was AllianceBernstein, adding an estimated $94.9M. The largest seller was Arrowstreet Capital, cutting an estimated $97.8M.
- 559 institutional investors held Novo Nordisk (NVO) as of Q2 2019, down from 580 in Q1 2019.
- Funds reported $8.89B of Novo Nordisk stock for Q2 2019, down 3.2% quarter-over-quarter.
- 53 funds opened new Novo Nordisk positions in Q2 2019 and 69 closed out, a net change of -16 holders.
- The largest Novo Nordisk buyer in Q2 2019 was AllianceBernstein, an estimated $94.9M added.
- The largest Novo Nordisk seller in Q2 2019 was Arrowstreet Capital, an estimated $97.8M sold.
Based on aggregated 13F filings for Q2 2019.